Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived fromrecombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely,a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations andsubstances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonalantibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medicaluse; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparationsfor the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the of Hereditary Angioedema, HAE